6533b854fe1ef96bd12aebb0
RESEARCH PRODUCT
Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
Serena MeravigliaElena Lo PrestiFrancesco Dielisubject
0301 basic medicineImmune defense2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)virusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyGamma delta T cells03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoveryMedicineCytotoxic T cellPharmacology (medical)PharmacologySARS-CoV-2business.industryRCOVID-19030104 developmental biologyInfectious Diseases030220 oncology & carcinogenesisPerspectiveImmunologyMedicinebusinessCD8description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had not yet been exploited in depth.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-05-01 | Vaccines |